Skip to : [Content] [Navigation]
 

 

Angel Group Aims to Give Medtech Start-Ups an Inside Track

Citing a dearth of investment organizations focused exclusively on supporting young life sciences companies, a coalition of 15 financial and scientific firms have launched an angel group to help seed and early-stage biotech and medical device companies position themselves for venture-backed funding.

The newly formed group calls itself Life Science Angels Inc. (LSA; Menlo Park, CA), and is sponsored by both technology and service providers to the life sciences industry. The group will target investments of approximately $250,000 to $1 million, and expects to distribute between $4 million and $6 million in 2005.

May
May: Filling the early-stage void.

“There is a huge need for an effective organization to fill the void between the early-stage need for capital and expertise and the need for well-vetted, high-quality opportunities for active investors in the life science area,” says Allan May, chairman and CEO of Vascular Architects Inc. (San Jose) and one of the founders of LSA. “We only began accepting investment opportunities in January and have over 50 deals in our pipeline, most contributed through our sponsors and members.” According to LSA’s Web site (www.lifescienceangels.com), the group anticipates investing in four to six companies this year.

According to May, LSA has also had success in recruiting investors eager to secure a stake in promising companies that might otherwise fall under the radar of traditional venture capitalists. “Our initial threshold to begin operations was 50 investors, with an ultimate limit of 80,” he says. At the end of January the group was already three-quarters of the way to its enrollment limit.

McGlynn
McGlynn: A vehicle for amateur investors.
Although there is no shortage of biotech investment funds operating today, Casey J. McGlynn, chairman of the life sciences practice at Wilson Sonsini Goodrich and Rosati (Palo Alto, CA) and another founder of the group, says that LSA will differ in that it is vertically, rather than horizontally, integrated. LSA membership is open to executives, scientists, engineers, and entrepreneurs only from the life sciences sector. McGlynn claims such a prerequisite will create a structure that, while modeled on classical venture capital funds, will serve as a vehicle for amateur investors.

“Our members, sponsors, and corporate partners will be encouraged to be actively involved in the management and operation of the group—with a real focus on participation both in the deal-solicitation and review process—as well as in the subsequent management and supervision of target companies,” explains McGlynn. As a result, he believes, LSA will be positioned to provide worthwhile mentoring to start-up medtech companies.

“The focus will be to assemble in one group all of the resources, contacts, and expertise that a life science entrepreneur needs to develop and grow an early-stage company, and to provide a platform for visibility to follow-on funding with professional venture capital funds,” says McGlynn.

Sponsors of Life Science Angels Inc. include a number of top-tier technology and service providers to the life sciences industry. Founding sponsors of the group are PricewaterhouseCoopers (New York City), Silicon Valley Bank (Santa Clara, CA), and Wilson Sonsini Goodrich and Rosati (Palo Alto, CA). The group’s current roster of sponsors lists the following firms.

BC Tech Inc.
BioQuest LLC
Boston Scientific Inc.
The Carlock Group
Centient Biotech Investor
CPS–Corfac International
Genentech
Heffernan Insurance Brokers
Horn Murdock Cole
Jefferies Broadview
Merrill Corp.
PricewaterhouseCoopers
Silicon Valley Bank
Wilson Sonsini Goodrich and Rosati
Windhover Information Inc.

© 2005 Canon Communications LLC

Return to main menu.

MX: Issues Update is a monthly
e-supplement prepared by the editors of MX: Business Strategies for Medical Technology Executives.

To become a regular subscriber to this monthly medtech business update, click here.